We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Craif Stock

Invest in or calculate the value of your shares in Craif or other pre-IPO companies through EquityZen's platform.

Get Started

Craif Stock

Craif is a biotechnology company that develops a cancer diagnosis algorithm using microRNA database and machine learning technology.

About Craif Stock

Founded

2018

Industries

Software, Artificial Intelligence, Data and Analytics

Icaria's mission is to create a new society in which people will not lose their lives by using urine tests to provide "early, painless and accurate early diagnosis of cancer."It is known that detecting cancer early increases the survival rate 5 to 10 times and greatly improves the prognosis. However, it is not unusual for many cancers to have no subjective symptoms, and when they become aware they have progressed to a stage where treatment is impossible. The most effective way to detect cancer at an early stage that can be treated is to have regular and high-precision cancer diagnosis, but existing cancer diagnosis is painful and However, many of them are not accurate enough and are not suitable for regular diagnosis and early stage diagnosis.

Craif Management

Leadership team at Craif

Representative Director,CEO & Co-founder

Onose Ryuichi

CSO & Co-founder

Takeshita Daiki

Locked Features

Join now and verify your accreditation status to gain access to:

  • Craif Current Valuation
  • Craif Stock Price
  • Craif Management
  • Available deals in Craif and all other companies with relevant Deal Offering documents
  • EquityZen's proprietary data and insights, which may include
    • Craif Cap Table and Funding History by Share Class and Liquidity Preferences
    • Craif Revenue and Financials
    • Craif Highlights
    • Craif Business Model
    • Craif Risk Factors
  • Craif Research Report from SACRA Research
Join Now

Trading Craif Stock

How to invest in Craif stock?

Accredited investors can buy pre-IPO stock in companies like Craif through EquityZen funds. These investments are made available by existing Craif shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Craif stock?

Shareholders can sell their Craif stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."